Author

Adel Atari

Broad Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:Bayesian inference· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:proteomics· 1

Frequent Co-Authors

Yuen‐Yi TsengiD· 2 shared Alessandro Sinopoli· 1 shared Brendan Dang· 1 shared Dennie Tompers FrederickiD· 1 shared Devishi KesariD· 1 shared Diego J. RodrigueziD· 1 shared Foxy P. RobinsoniD· 1 shared Harini NarayananiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Yuen‐Yi TsengORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Accelerating Cell Culture Media Development Using Bayesian Optimization-Based Iterative Experimental Design

Harini Narayanan, Joshua A. Hinckley, Rachel M. Barry, Brendan Dang, Lenna A. Wolffe, Adel Atari, Yuen‐Yi Tseng, John Christopher Love

This paper uses Bayesian optimization to accelerate cell culture media development, achieving better results with fewer experiments in two applications.

Nature Communications · Jul 1, 2025Peer-reviewedBioengineering

Identification of potent biparatopic antibodies targeting FGFR2 fusion driven cholangiocarcinoma.

Saireudee Chaturantabut, Sydney Oliver, Dennie Tompers Frederick, Jiwan Kim, Foxy P. Robinson, Alessandro Sinopoli, Tianyu Song, Yao He, Y.H. Chang, Diego J. Rodriguez, Liang Chang, Devishi Kesar, Meilani Ching, Ruvimbo Dzvurumi, Adel Atari, , William R. Sellers

The paper identifies biparatopic antibodies targeting FGFR2 extracellular domain that effectively block FGFR2 fusion-driven cholangiocarcinoma signaling and growth.

Journal of Clinical Investigation · Feb 27, 2025Peer-reviewedCancer Biology